A detailed history of Geode Capital Management, LLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 666,310 shares of ATNM stock, worth $1.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
666,310
Previous 595,720 11.85%
Holding current value
$1.19 Million
Previous $4.66 Million 5.7%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$6.56 - $9.89 $463,070 - $698,135
70,590 Added 11.85%
666,310 $4.93 Million
Q1 2024

May 13, 2024

BUY
$5.0 - $9.2 $130,855 - $240,773
26,171 Added 4.6%
595,720 $4.66 Million
Q4 2023

Feb 13, 2024

BUY
$4.02 - $6.08 $108,982 - $164,828
27,110 Added 5.0%
569,549 $2.89 Million
Q3 2023

Nov 13, 2023

BUY
$5.91 - $7.37 $124,452 - $155,197
21,058 Added 4.04%
542,439 $3.21 Million
Q2 2023

Aug 11, 2023

BUY
$7.15 - $9.39 $2.07 Million - $2.71 Million
288,949 Added 124.32%
521,381 $3.87 Million
Q1 2023

May 15, 2023

BUY
$8.51 - $14.26 $6,348 - $10,637
746 Added 0.32%
232,432 $2.2 Million
Q4 2022

Feb 13, 2023

BUY
$7.05 - $14.41 $123,516 - $252,463
17,520 Added 8.18%
231,686 $2.47 Million
Q3 2022

Nov 14, 2022

BUY
$4.81 - $8.48 $201,774 - $355,727
41,949 Added 24.36%
214,166 $1.58 Million
Q2 2022

Aug 12, 2022

BUY
$4.71 - $7.11 $23,761 - $35,869
5,045 Added 3.02%
172,217 $828,000
Q3 2021

Nov 12, 2021

BUY
$5.76 - $9.67 $83,485 - $140,156
14,494 Added 9.49%
167,172 $1.48 Million
Q2 2021

Aug 13, 2021

BUY
$7.01 - $8.63 $370,632 - $456,285
52,872 Added 52.97%
152,678 $1.21 Million
Q3 2020

Nov 13, 2020

BUY
$7.26 - $18.0 $724,591 - $1.8 Million
99,806 New
99,806 $967,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $44.8M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.